In Vitro Susceptibility of Clostridium Difficile Clinical Isolates from a Multi-institutional Outbreak in Southern Québec, Canada

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2006 Sep 29

PMID 17005836

Citations 32

Authors

Anne-Marie Bourgault

Francois Lamothe

Vivian G Loo

Louise Poirier

Affiliations

Soon will be listed here.

Abstract

Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.

Citing Articles

An epidemiological surveillance study (2021-2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China.

Cui Y, Zhang C, Jia Q, Gong X, Tan Y, Hua X BMC Infect Dis. 2023; 23(1):703.

PMID: 37858038 PMC: 10588108. DOI: 10.1186/s12879-023-08666-2.

Clostridioides difficile carriage in animals and the associated changes in the host fecal microbiota.

Thanissery R, McLaren M, Rivera A, Reed A, Betrapally N, Burdette T Anaerobe. 2020; 66:102279.

PMID: 33022384 PMC: 10760528. DOI: 10.1016/j.anaerobe.2020.102279.

Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.

Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L Antimicrob Resist Infect Control. 2020; 9(1):158.

PMID: 32977835 PMC: 7517813. DOI: 10.1186/s13756-020-00815-5.

Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.

Peng Z, Simeon R, Mitchell S, Zhang J, Feng H, Chen Z mSphere. 2019; 4(5).

PMID: 31578248 PMC: 6796971. DOI: 10.1128/mSphere.00596-19.

Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital.

Sheth P, Douchant K, Uyanwune Y, Larocque M, Anantharajah A, Borgundvaag E PLoS One. 2019; 14(2):e0207138.

PMID: 30742636 PMC: 6370182. DOI: 10.1371/journal.pone.0207138.

References

Freeman J, Wilcox M . Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother. 2001; 47(2):244-6. DOI: 10.1093/jac/47.2.244. View

Bartlett J, Perl T . The new Clostridium difficile--what does it mean?. N Engl J Med. 2005; 353(23):2503-5. DOI: 10.1056/NEJMe058221. View

Fawley W, Wilcox M . Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains. J Clin Microbiol. 2002; 40(9):3546-7; author reply 3547. PMC: 130783. DOI: 10.1128/JCM.40.9.3546-3547.2002. View

Loo V, Libman M, Miller M, Bourgault A, Frenette C, Kelly M . Clostridium difficile: a formidable foe. CMAJ. 2004; 171(1):47-8. PMC: 437684. DOI: 10.1503/cmaj.1040836. View

Pepin J, Valiquette L, Alary M, Villemure P, Pelletier A, Forget K . Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004; 171(5):466-72. PMC: 514643. DOI: 10.1503/cmaj.1041104. View

Tenover F, Arbeit R, Goering R, Mickelsen P, Murray B, Persing D . Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995; 33(9):2233-9. PMC: 228385. DOI: 10.1128/jcm.33.9.2233-2239.1995. View

Barbut F, Corthier G, Charpak Y, Cerf M, Monteil H, Fosse T . Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med. 1996; 156(13):1449-54. View

Coutant C, Olden D, Bell J, Turnidge J . Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method. Diagn Microbiol Infect Dis. 1996; 25(1):9-13. DOI: 10.1016/0732-8893(96)00070-3. View

Musher D, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F . Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005; 40(11):1586-90. DOI: 10.1086/430311. View

10.

Pepin J, Alary M, Valiquette L, Raiche E, Ruel J, Fulop K . Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40(11):1591-7. DOI: 10.1086/430315. View

11.

Gerding D . Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?. Clin Infect Dis. 2005; 40(11):1598-600. DOI: 10.1086/430317. View

12.

John R, Brazier J . Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect. 2005; 61(1):11-4. DOI: 10.1016/j.jhin.2005.01.020. View

13.

Pepin J, Saheb N, Coulombe M, Alary M, Corriveau M, Authier S . Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005; 41(9):1254-60. DOI: 10.1086/496986. View

14.

Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S . A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23):2442-9. DOI: 10.1056/NEJMoa051639. View

15.

McDonald L, Killgore G, Thompson A, Owens Jr R, Kazakova S, Sambol S . An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005; 353(23):2433-41. DOI: 10.1056/NEJMoa051590. View

16.

Leroi M, Siarakas S, Gottlieb T . E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Eur J Clin Microbiol Infect Dis. 2002; 21(1):72-4. DOI: 10.1007/s10096-001-0658-0. View